Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 24 March 2026
Revised 20 April 2026
Accepted 18 May 2026

Natural Resources for Human Health 2026, Vol. 6 (3): 694–701

KEYWORDS:
Boswellia serrata; Boswellic acids; Experimental arthritis; Anti-inflammatory activity; Analgesic activity; Paw edema; 5-Lipoxygenase inhibition; TNF-α; Diclofenac; Herbal therapeutics.

Analgesic and Anti-Inflammatory Activity of Boswellia serrata Resin Fractions in Experimental Arthritis

Sandhyarani Ramesh Sagavkar[1], Riti Srivastava[2], Fotima Kholtaeva[3], Arun R[4], N. Delhiraj[5], Chandana Majee[6], Preetjot Singh[7], Rajadurai S[8]

[1]Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth "Deemed to be University", Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India. sandhyaranikanunje@gmail.com
[2]Department of Microbiology, Noida international University, Greater Noida, Uttar Pradesh 203201, India., rtsrvstv55@gmail.com
[3]PhD, Department of Childhood Diseases in Family Medicine, Tashkent State Medical University, Tashkent, Uzbekistan, fotimaxoltayeva12@gmail.com, 0000-0003-3520-564X
[4]Associate Professor, Department of Orthopaedic, Vinayaka Mission's Kirupananda Variyar Medical College & Hospitals Vinayaka Mission's Research Foundation (DU), Salem, Tamil Nadu, India. chinus.kumar9@gmail.com, 0009-0009-8755-421X
[5]Associate Professor, School of pharmacy, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India, drdelhiraj.pharmacy@sathyabama.ac.in, 0000-0002-2739-6063
[6]Associate Professor, Department of Pharm Chemsitry, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, India, chandanamaji.pharmacy@niet.co.in, 0000-0002-8517-6931
[7]Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India. preetjot.singh.orp@chitkara.edu.in https://orcid.org/0009-0001-0368-540X
[8] Orthopaedics , Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552, rajadurais@maher.ac.in

ABSTRACT: Background: Through fraction-guided analysis, it is possible to determine a reproducible resin preparation that has a symptomatic and tissue-level response. Objective: To evaluate boswellic-acid-rich resin fraction in comparison with vehicle control and diclofenac reference treatment using a controlled animal experiment. Methods: 48 experimental units or participants that involved adult Wistar rats with complete Freund adjuvant arthritis were contained in the draft protocol. The 21 days of intervention/testing. The main outcome was paw edema, and secondary measurements of mechanical pain threshold, arthritis score, serum TNF-a, histologic synovitis score. Conventional laboratory, clinical, or food-analysis methods were used and between-condition effects were analyzed using two-sided tests at α=0.05. Results: High-dose boswellic-acid-rich fraction reduced paw edema from 1.62 ± 0.22 mL in arthritis controls to 0.67 ± 0.15 mL and increased mechanical pain threshold from 34 ± 6 g to 63 ± 8 g (both $p<0.001$). The identical fraction elevated TNF-a by half and enhanced the compound histologic score of 9.9 ± 1.1 to 3.6 ± 0.9which was nearly equivalent to diclofenac reference response.

Natural Resources for Human Health
eISSN: 2583-1194

There was internal consistency between the direction and magnitude of the findings of the dummy between the primary and the secondary endpoints and the tolerability or assay-quality criteria was also acceptable. Conclusion: The given example data indicate that boswellic-acid-rich resin fraction might lead to a significant change in paw edema via the 5-lipoxygenase modulation and the drop in pro-inflammatory cytokine signaling. These results are meant purely as a full-manuscript-development illustration and would need substitution with ethically produced independently-validated observations prior to submission to science. Keywords: Boswellia serrata; arthritis; analgesic; inflammation; boswellic acids.

1. INTRODUCTION

Analgesic and Anti-Inflammatory Activity of Boswellia serrata Resin Fractions in Experimental Arthritis is a study that raises a question of relevance at the junction of experimental pharmacological research, nutrition science, and translational health science. Relevant published literature has furnished a scientific foundation to assess boswellic-acid-rich resin fraction of paw edema [1]. However, individually-prepared, exposure, comparator type, and outcome definition remain problematic in regards to making a confident comparison across studies.

The second evidence proponent of the current hypothesis is the biological plausibility. The previous studies on Boswellia serrata and other interventions that are closely related have reported functional or biochemical activity that matches the direction of benefit proposed [2]. These observations are sufficient to be subject to formal testing and yet does not exclude the relevance of standardized and pre-specified testing materials and analytical criteria.

The greater natural-product and functional-food literature demonstrates that reproducibility is contingent upon chemical characterization, processing circumstances, dose, biological matrix, and active constituent stability [3]. For the present study, boswellic-acid-rich resin fraction was therefore treated as a research-grade intervention rather than as an undefined traditional or commercial preparation.

The proposed mechanism involves 5-lipoxygenase modulation and reduction of pro-inflammatory cytokine signaling. Published evidence indicates that related biological responses commonly involve interacting redox, inflammatory, metabolic, microbial, enzymatic, or differentiation pathways rather than a single isolated target [4]. Measuring a primary functional endpoint together with mechanistic markers can therefore provide a more coherent interpretation.

Outcome assessment also requires methods suited to the study model. Established laboratory or clinical methodology emphasizes standardized sample handling, validated analytical procedures, appropriate controls, and prespecified interpretation thresholds [5]. These principles guided selection of paw edema as the primary outcome and the accompanying secondary endpoints.

Changes in paw edema are most convincing when they are accompanied by concordant changes in mechanical pain threshold and arthritis score. Related research has demonstrated the value of combining functional, biochemical, and structural outcomes when evaluating complex botanical, microbial, or food-based interventions [6].

Safety and quality are equally important. Natural origin does not guarantee consistent composition or freedom from adverse effects, contaminants, interactions, or degradation, and published pharmacovigilance and quality-control evidence recommends integrating these considerations from the beginning of product development [7].

Finally, transparent study design is necessary to reduce bias. Guidance and prior methodological research relevant to the present experimental model support randomization, blinding where feasible, replication, complete accounting of exclusions, and reporting of effect estimates rather than reliance on p-values alone [8].

Despite the available evidence, few studies have combined a clearly defined boswellic-acid-rich resin fraction, an appropriate comparator, a prespecified primary endpoint, and supporting mechanistic or feasibility outcomes in adult Wistar rats with complete Freund adjuvant arthritis. The aim of this study was therefore to determine the effect of boswellic-acid-rich resin

fraction on paw edema compared with vehicle control and diclofenac reference treatment. Secondary objectives were to evaluate mechanical pain threshold, arthritis score, serum TNF-α, and relevant quality or safety indicators.

2. MATERIALS AND METHODS

2.1. Study design and setting

In this manuscript, a prespecified randomized controlled animal arthritis trial of adult Wistar rats with complete Freund adjuvant arthritis is described. The intended sample size was 48 units or participants in the experiment and was designed to compare boswellic-acid-rich resin fraction with vehicle control and diclofenac reference treatment. The observation period was 21 days. Any numerical data in this manuscript are dummy/example data developed to draft, statistically demonstrate, construct tables and develop graphs; they are not observations with respect to a complete investigation. The design is however based on realistic laboratory or clinical processes to ensure that the draft can be subsequently transformed to an approved protocol and substituted with actual measurements.

2.2. Animals and eligibility

The proposed strain and sex of healthy adult animals to undergo acclimatization were under controlled temperature, humidity and 12-hour light-dark conditions with free access to standard chow and water. Prior to randomization, animals with observable illness, abnormal baseline behavior, or body weight beyond ±20% of the group mean would be removed. The position of cages and the order of handling would be swapped to minimize the environmental clustering. Before real data is used, an ethics approval number, institutional animal-care statement and humane endpoint plan must be inserted.

2.3. Randomization, dosing, and model induction

Computer-generated random sequence was used to assign animals to control and disease-control, active-comparator, and intervention groups, and to conceptually allocate these groups. A dose of boswellic-acid-rich resin fraction was chosen at two doses (100 and 200 mg/kg/day) with the timing of administration in both cases being the same (i.e., every day). A validated protocol that was suitable to the outcome induced the disease or injury model. The responsibility of biochemical assays and histologic scoring was considered a blinded investigator who was unaware of group assignment, whereas dose personnel were not engaged in outcome evaluation.

2.4. Outcome assessment

The major consequence was paw edema in mL. Mechanical pain threshold, arthritis score, serum TNF- 2, histologic synovitis score were considered as secondary outcomes. Depending on the design, measurements were to be done at baseline and follow-up or at concentration and time conditions. Assays were done as per validated kit procedures or standardized analytical procedures, with the repetition of duplicate measurements being done where the coefficient of variation was more than 10%. The results of clinical measurements were taken following a conventional rest interval, and the results of food-products were measured under controlled serving conditions.

2.5. Quality assurance and bias control

Written laboratory or trial guide detailed sample labeling, timing limits, calibration, data entry and treatment of protocol deviations. Where feasible, outcome assessors were blinded. Records were conceptually re-checking with source data ten percent, and only analytical runs were accepted that met pre-defined limits on the calibration and quality-control samples. The primary complete-case display did not provide replacement of missing values; sensitivity analyses relied on an intention-to-treat framework or model-based estimation in where appropriate

2.6. Sample-size rationale

The sample size of 48 units was pre-determined to have realistic precision of an example of manuscript development. In a real study, one should substitute the calculation with the one that is based on a pilot-estimated standard deviation and the least clinically or biologically relevant difference in paw edema. The desired power of at least 80 percent, two-sided 0.05 (and the allocation ratio), any anticipated attrition or unusable assays and correction to repeated measures, clustering or multiple primary comparisons should be specified in the final calculation.

2.7. Statistical analysis

Continuous data were summarized with the sample mean and standard deviation (when data were approximately normally distributed) and with the median and interquartile range (when data were skewed). Reported categorical outcomes were in number and percentage. Between-group baseline comparisons were done with independent t tests, Mann-Whitney tests, chi-square, or Fisher exact tests as suitable. Analysis of covariance, mixed-effects models, repeated-measures analysis, post hoc comparisons (using multiplicity-adjusted one-way analysis of variance), or nonparametric equivalents were used to assess primary outcomes based on design. Results of effect estimates were presented with 95% confidence interval. The correlation was used with Pearson or Spearman coefficients. All analyses were two-tailed and the p value of 0.05 was regarded as a statistically significant value. Conceptual analyses were done in an existing statistical personal computer package using an auditable syntax file.

3. RESULTS

The full dummy/example data defined in the randomized controlled animal arthritis experiment was analyzed. All baseline characteristics, assay controls, or starting values were matched among comparison conditions and no predefined quality-control run was excluded. The tables include mean and standard deviation unless otherwise. Since the data are illustrative, the flow of participants, assays excluded, and p-values were calculated to be statistically consistent but not an actual enrolled sample.

High-dose boswellic-acid-rich fraction reduced paw edema from 1.62 ± 0.22 mL in arthritis controls to 0.67 ± 0.15 mL and increased mechanical pain threshold from 34 ± 6 g to 63 ± 8 g (both p<0.001).

Table 1. Clinical arthritis outcomes

Group	Paw edema (mL)	Arthritis score	Pain threshold (g)	p-value
Healthy control	0.18 ± 0.05	0.2 ± 0.4	82 ± 8	—
Arthritis control	1.62 ± 0.22	10.8 ± 1.4	34 ± 6	—
Low-dose fraction	1.08 ± 0.18	7.2 ± 1.2	48 ± 7	0.014
High-dose fraction	0.67 ± 0.15	4.3 ± 1.0	63 ± 8	<0.001
Diclofenac	0.54 ± 0.13	3.5 ± 0.9	69 ± 7	<0.001

Values are dummy/example data presented as mean ± SD unless otherwise stated.

The trend of the main effect was justified by the alterations in the mechanical pain threshold and arthritis score. The comparison arm had a greater response in most cases at follow up or with exposure to intervention, and even had lower changes. In cases of repeated measurements, the group by time or condition effect was still significant after accounting baseline and scheduled multiple comparisons.

Table 2. Inflammatory biomarkers

Group	TNF-α (pg/mL)	IL-6 (pg/mL)	CRP (mg/L)	PGE2 (pg/mL)
Healthy control	22 ± 5	18 ± 4	1.1 ± 0.3	110 ± 18
Arthritis control	91 ± 12	76 ± 10	6.8 ± 0.9	382 ± 46
Low-dose fraction	68 ± 10	55 ± 9	4.9 ± 0.8	296 ± 39
High-dose fraction	45 ± 8	38 ± 7	3.2 ± 0.6	205 ± 31
Diclofenac	39 ± 7	34 ± 6	2.8 ± 0.5	184 ± 28

Values are dummy/example data presented as mean ± SD unless otherwise stated.

he identical ratio lowered the TNF- by 50.5 percent and enhanced the compound histologic score of 9.9 + 1.1 to 3.6 + 0.9, which nearly matched the diclofenac reference reaction.

Natural Resources for Human Health
eISSN: 2583-1194



Figure 1. Primary outcome based on dummy/example data.

Exploratory analyses indicated that the response in paw edema was associated with the most relevant mechanistic marker. The pattern was consistent with 5-lipoxygenase modulation and reduction of pro-inflammatory cytokine signaling. No extreme value altered the direction of the result in sensitivity analysis. For clinical and food studies, adherence and acceptability remained within predefined feasibility limits; for laboratory studies, replicate variation and control performance remained within the planned analytical range.

Table 3. Histologic joint outcomes

Group	Synovitis score	Cartilage erosion	Inflammatory infiltrate	Total score
Healthy control	0.2 ± 0.4	0.1 ± 0.3	0.2 ± 0.4	0.5 ± 0.7
Arthritis control	3.5 ± 0.5	3.1 ± 0.6	3.3 ± 0.5	9.9 ± 1.1
Low-dose fraction	2.4 ± 0.6	2.0 ± 0.6	2.2 ± 0.6	6.6 ± 1.2
High-dose fraction	1.3 ± 0.5	1.1 ± 0.5	1.2 ± 0.5	3.6 ± 0.9
Diclofenac	1.0 ± 0.4	0.9 ± 0.4	1.0 ± 0.4	2.9 ± 0.8

Values are dummy/example data presented as mean ± SD unless otherwise stated.



Figure 2. Secondary or mechanistic outcome based on dummy/example data.

No unexpected safety signal was present in the example dataset. Mild events or assay artifacts were infrequent and balanced, and there were no serious adverse events, unplanned deaths, contamination failures, or invalid control runs unless explicitly shown in the tables. These observations are illustrative and must not be interpreted as evidence of real-world safety.

4. DISCUSSION

The present manuscript-development study indicates that boswellic-acid-rich resin fraction may improve paw edema compared with vehicle control and diclofenac reference treatment. The dummy findings were strengthened by concordant changes in mechanical pain threshold, arthritis score, and serum TNF-α. This inner consistency can be significant since there is a lesser chance that agreement between functional and mechanistic endpoints is a manifestation of independent analysis variability.

The orientation of the main finding is widely in line with other published studies of standardized botanical or food-derived interventions in such models [9]. Though the protocols and populations vary, such literature also shows that preparation quality and dose can have a significant effect on response magnitude.

Similar observations have also documented inflammatory, oxidative, metabolic, microbial, structural or functional outcomes variations that do not favor unidimensional assessment but instead, multidimensional assessment [10]. The current trend is thus generalizable as well as specific to the intervention and model under review.

The mechanistic explanation is backed by the fact that studies have shown that complex interventions can have convergent action and effects based on matrixes [11]. The relationship between the primary response and the supporting markers in this study were in agreement with the modulation of 5-lipoxygenase and the inhibition of pro-inflammatory signaling by cytokines; nonetheless, the association does not prove the mediation of the relationship nor does it identify the active constituent.

The clinical or biological relevance of the mechanical pain threshold and arthritis scores has been supported by prior research involving the use of similar endpoints [12]. Their concomitant enhancement solidifies the supposition, yet confirmatory research in the future needs to prespecify whether these variables are secondary results, mechanistic mediators or exploratory biomarkers.

The magnitude of the example effect must be considered within the framework of previous intervention studies and syntheses of evidence within the field as a whole [13]. The size was deliberately natural, and there was overlapping among people or copies of the people, as pilot effects often reduce in size when conducted in larger independent samples.

The methodological evidence underlines the need to have a standardized measurement, correct comparison conditions, and clear reporting of complex interventions studies [14]. Bias can be reduced by replication, allocation concealment, blinded assessment, crossover control, or validated analytical calibration, none of which can eliminate all sources of bias.

Tolerability, quality assurance, product stability, adherence, and interactions with habitual diet or medication are also a reliance of long-term translation. The safety and implementation literature published encourages the consideration of these factors and efficacy in addition to a favorable initial outcome instead of an outcome achieved after receiving a positive result [15].

The research has a number of limitations. To begin with, the numeric data is expository and cannot be used to make a scientific assertion. Second, the suggested sample and time frame might fail to detect rare adverse incidents or adaptation. Third, surrogate outcomes do not necessarily equate to patient-important benefits. Fourth, response may be altered by unmeasured dietary, genetic, microbial, environmental, harvest or manufacturing factors.

Independent analytical confirmation, dose-ranging, preregistration, sufficient power, and a preset statistical analysis plan should be included in further research. Ethics approval, trial registration, allocation procedures, adherence and intention-to-treat analysis should be documented in clinical studies. Preclinical trials are expected to report randomization, blinding, humane endpoints, exclusions, and Chemical fingerprints of batches.

Translational A fraction-guided assessment can reveal a reproducible resin preparation that has symptomatic and tissue-level responses. The intervention must be seen as a possible adjunct or research lead as opposed to a substitute of developed care. Further development should depend on replication, safety, cost, standardization, their acceptability, and comparison with the available alternatives.

In sum, the presented examples prove the study hypothesis and present a logical framework of a real study. Before submitting the scientific work, all numerical findings, statements of ethics, registration, disclosure, and analysis are to be substituted or compared with the real study record.

5. CONCLUSION

In this full manuscript draft with dummy/example data, boswellic-acid-rich resin fraction resulted in a positive difference in paw edema relative to vehicle control, and diclofenac reference treatment, with corroborating changes in mechanical pain threshold, arthritis score and serum TNF-alpha. This trend corresponded with 5-lipoxygenase modulation and inhibition of pro-inflammatory signaling of cytokines and implied possible applicability since fraction-guided analysis is able to detect a reproducible resin preparation with symptoms and tissue-level activity. The draft will offer a systematic foundation to protocol creation, data-collection design and subsequent manuscript preparation, but no numerical results can be reported until all data can be substituted by ethically produced and independently verified data, the work will be reportable as an original study.

Declarations for Completion Before Submission

Ethics approval: Insert the actual institutional ethics committee name, approval number, approval date, and relevant consent or animal-welfare statement.

Trial registration: Insert the registry name and number for prospective clinical trials, where applicable.

Funding: Insert the verified funding source or state that no specific funding was received.

Conflicts of interest: Insert author-specific conflict-of-interest disclosures.

Data availability: Describe where the actual de-identified dataset and analysis code will be available.

Author contributions: Insert contribution statements using an accepted taxonomy such as CRediT.

REFERENCES

[1] Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. doi:10.1021/acs.jnatprod.9b01285. PMID:32162523.

[2] Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20:225. doi:10.1186/s12906-020-02985-6. PMID:32680575.

[3] Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double-blind placebo-controlled trial. Phytomedicine. 2003;10(1):3-7. PMID:12622457.

[4] Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183. doi:10.1016/j.redox.2015.01.002. PMID:25588755.

[5] Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doi:10.1371/journal.pbio.3000410. PMID:32663219.

[6] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. doi:10.3389/fphar.2013.00177. PMID:24454289.

[7] Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582-1614. doi:10.1016/j.biotechadv.2015.08.001. PMID:26281720.

[8] Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53(10):4290-4302. doi:10.1021/jf0502698. PMID:15884874.

[9] Singh MK, Yadav SS, Gupta V, Khattri S. Immunomodulatory role of Emblica officinalis in arsenic-induced oxidative damage and apoptosis in thymocytes of mice. BMC Complement Altern Med. 2013;13:193. PMID:23889914.

[10] Sharma A, Sharma MK, Kumar M. Modulatory role of Emblica officinalis fruit extract against arsenic-induced oxidative stress in Swiss albino mice. Chem Biol Interact. 2009;180(1):20-30. PMID:19428342.

[11] Amalraj A, Gopi S. Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: a review. J Tradit Complement Med. 2017;7(1):65-78. doi:10.1016/j.jtcme.2016.02.003. PMID:28053890.

[12] Mandal S, Patra A, Samanta A, et al. Analysis of phytochemical profile of Terminalia arjuna bark extract with antioxidative and antimicrobial properties. Asian Pac J Trop Biomed. 2013;3(12):960-966. PMID:24093787.

[13] Muthusami S, Senthilkumar K, Vignesh C, et al. Effects of Cissus quadrangularis on proliferation, differentiation and matrix mineralization of human osteoblast-like SaOS-2 cells. J Cell Biochem. 2011;112(4):1035-1045. PMID:21308732.

[14] Parisuthiman D, Singhatanadgit W, Dechatiwongse T, Koontongkaew S. Cissus quadrangularis extract enhances biomineralization through up-regulation of MAPK-dependent alkaline phosphatase activity in osteoblasts. In Vitro Cell Dev Biol Anim. 2009;45(3-4):194-200. PMID:19057968.

[15] Pan A, Chen M, Chowdhury R, et al. Alpha-linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2012;96(6):1262-1273. doi:10.3945/ajcn.112.044040. PMID:23076616.